TRIOSTAT Drug Patent Profile

When do Triostat patents expire, and what generic alternatives are available?

Triostat is a drug marketed by Ph Health and is included in one NDA.

The generic ingredient in TRIOSTAT is liothyronine sodium. Nineteen suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Triostat

A generic version of TRIOSTAT was approved as liothyronine sodium by XGEN PHARMS on August 17^th, 2005.

Summary for TRIOSTAT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TRIOSTAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	TRIOSTAT	liothyronine sodium	INJECTABLE;INJECTION	020105-001	Dec 31, 1991		DISCN	Yes	No

Last updated: July 28, 2026

TRIOSTAT (Triostat): investment scenario and patent/IP risk, FDA status, and commercial fundamentals

TRIOSTAT is an oxybutynin hydrochloride product name associated with the overactive bladder (OAB) market. The investability profile is driven by (1) how TRIOSTAT is positioned versus generic oxybutynin immediate-release and extended-release tablets and (2) whether TRIOSTAT has any enforceable secondary IP (formulation, dosing regimen, or device-like delivery) beyond the active ingredient. Without a confirmed FDA reference product, strength, dosage form, NDC-to-Orange-Book mapping, and listed patents for TRIOSTAT specifically, the patent landscape and exclusivity schedule cannot be stated with precision.

What can be stated from an investment-modeling standpoint is the risk structure investors typically underwrite for legacy OAB antimuscarinics: generic substitution pressure, payer/plan formularies favoring AB-rated generics, limited incremental clinical differentiation, and potential parallel exclusivity only if a truly branded formulation or combination is involved.

---

What is TRIOSTAT and how does it compete in overactive bladder (OAB)?

Drug class and therapeutic use

• TRIOSTAT is an antimuscarinic therapy used for OAB indications (frequency, urgency, and urge incontinence).

Competitive set investors underwrite

For antimuscarinics in OAB, demand is highly sensitive to:

• AB-rating and step therapy on formularies
• generics pricing and net-to-gross erosion
• adherence and tolerability profiles (dry mouth, constipation, cognitive effects in older patients)

Key comparable reference lines for market modeling:

• Oxybutynin immediate-release (IR) tablets
• Oxybutynin extended-release (ER) formulations
• Transdermal oxybutynin
• Trospium and solifenacin as adjacent antimuscarinics
• Beta-3 agonists (mirabegron, vibegron) as the main mechanism-aligned shift away from antimuscarinics

Where branded antimuscarinics lose most value

• Patent cliffs at the active ingredient and core formulation level
• Rapid generic entry once Orange Book coverage is cleared
• Limited ability to defend pricing after formulary replacement

---

What patents protect TRIOSTAT (oxybutilnin) and how strong is the patent estate?

Patent estate strength checklist

For a TRIOSTAT investment thesis, strength depends on whether at least one of the following exists and is enforceable past the relevant forecast horizon:

1. Formulation patents covering release characteristics or specific excipient systems
2. Method-of-use patents tied to dosing regimens or patient subpopulations
3. Manufacturing/process patents that create non-trivial generic barriers
4. Pediatric exclusivity or other statutory extensions (rare for legacy antimuscarinics unless a branded product obtained later approval)

How investors score TRIOSTAT for IP risk

A typical scoring rubric uses:

• Number of unexpired Orange Book patents by claim type (composition/formulation vs method)
• Expiration dates and whether any patents are subject to pending term adjustments (PTA) or terminal disclaimers
• Whether patents have survived prior litigation or are “late-cycle” filings vulnerable to invalidity challenges
• Whether TRIOSTAT is itself a unique branded formulation or only an AB-rated product name tied to generic-active ingredient continuity

Actionable investment implication

If TRIOSTAT is an AB-rated antimuscarinic with no unique formulation IP, expected downside is high: pricing erodes quickly after generic entry. If TRIOSTAT is a differentiated formulation with multiple enforceable patents expiring later, upside improves through extended exclusivity and delay of Paragraph IV filings.

---

When does TRIOSTAT lose exclusivity or face generic entry risk?

Exclusivity drivers investors use

For small-molecule OAB drugs, generic entry risk timing is usually driven by:

• Orange Book patent expirations (not statutory exclusivity alone)
• Proprietary data exclusivity only if the branded product is tied to a New Drug Application (NDA) category with applicable exclusivity periods
• Pediatric exclusivity only if granted and properly listed

Key modeling dates

• Earliest patent expiration among listed composition/formulation patents
• Any later-expiring method-of-use patents
• Any terminal disclaimer end-date that caps enforceability
• Lag between expiration and generic launch (often 6 to 24 months depending on approval and supply readiness)

How to underwrite the entry scenario

• Base case: generic entry at earliest clearance (patent expiry or settlement date)
• Downside: earlier-than-expected clearance due to patent weakness or invalidation in litigation
• Upside: delayed entry from settlements or injunctions tied to specific claims

---

What is the Orange Book status of TRIOSTAT (patents, listed claim scope, and expiration dates)?

Orange Book elements that matter for TRIOSTAT

Investors typically require:

• Active ingredient listing (oxybutilnin salt form and strength)
• Dosage form mapping (IR vs ER, tablets vs liquid)
• Orange Book listed patents by:
  • US patent numbers
  • patent types (composition/formulation, method of use, process)
  • expiration dates and any PTA/PTD
  • exclusivity codes for non-patent exclusivity

What this means for diligence

If TRIOSTAT is listed with multiple overlapping patents extending beyond 5 years, investors model slower erosion. If TRIOSTAT has only active-ingredient patents expiring quickly, the economics behave like a conventional generics product with limited brand durability.

---

Has TRIOSTAT faced Paragraph IV challenges or generic litigation?

Paragraph IV risk framework for OAB

For OAB antimuscarinics, Paragraph IV challenges are common once patents are listed and generics can justify “no infringement” or “invalid” theories.

Investors evaluate:

• Whether there are current or historical Paragraph IV notices
• Whether TRIOSTAT’s NDA is protected by multiple patents or just one
• Whether courts have issued claim construction favorable to the patentee
• Whether settlement terms include “180-day exclusivity” handoffs

Investment implication

• High litigation intensity plus survival of key claims = improved risk-adjusted returns.
• Litigation absence or quick settlements = likely early generic normalization.

---

What FDA regulatory pathway supports TRIOSTAT and what is its approval history?

Regulatory pathway questions that drive risk

• Is TRIOSTAT an NDA-branded product or a branded generic?
• What is the approval year and reference NDA?
• Does TRIOSTAT have an NDA category implying data exclusivity beyond patents?

Investment modeling use

Approval history is used to estimate:

• whether exclusivity already expired
• whether TRIOSTAT is “late-cycle” and thus more exposed to near-term competition

---

How does TRIOSTAT compare with other OAB therapies on competitive positioning and switch rates?

Mechanism and payer behavior

Antimuscarinics face payer preference shifts toward:

• beta-3 agonists (mirabegron/vibegron)
• persistence and adverse event profiles
• step therapy rules that favor lower-cost AB-rated options

Net pricing sensitivity

Branded OAB drugs typically experience:

• rapid gross-to-net changes once AB competition expands
• increased rebate pressure when interchangeability becomes available in major channels

Investment implication

Unless TRIOSTAT has differentiated clinical or practical benefits tied to formulation, investors should model:

• continued formulary substitution
• pressure on gross margins upon generic availability

---

Formulation and manufacturing: what could block generic substitution for TRIOSTAT?

Common generic substitution blockers

• Proprietary release mechanism (for ER products)
• Specific particle size distributions
• Solid-state form control (polymorphs, hydrates)
• Manufacturing controls that are non-trivial to replicate

Investment relevance

Manufacturing/process patents matter only if:

• they are properly listed in the Orange Book
• they have enforceable claims covering generic production steps
• they have survived validity and infringement defenses

For legacy antimuscarinics, the most common reality is generic feasibility once the active ingredient is protected only by expiring composition patents.

---

Who are the likely competitors and what is the typical entry/erosion curve?

Brand-to-generic erosion shape in OAB

Generic entry often causes:

• immediate price compression toward AWP-to-NADAC adjusted benchmarks
• accelerated share loss during formulary conversion windows
• slower retention among patients with tolerability constraints (dry mouth, constipation), but typically not enough to preserve a premium

Competition mapping

Investors typically map:

• AB-rated oxybutynin products by dosage form and strength
• adjacent competitive mechanisms (beta-3 agonists) that may reduce total addressable market growth for antimuscarinics

---

What generic entry risks exist for TRIOSTAT and what are the likely launch scenarios?

Launch scenarios investors model

• Scenario A: earliest patent expiration followed by first generic launch
• Scenario B: launch delayed by settlements or injunctions, then “cluster” launches after key claim expiry
• Scenario C: at-risk launch where litigation risk affects distribution and pharmacy adoption

What drives scenario selection

• strength of enforceable formulation/method claims
• court timelines and settlement propensity
• generic sponsor strategy (design-around vs entry timing)

---

Licensing and settlement dynamics: what deal structures matter for TRIOSTAT?

Deal structures that change valuation

• License agreements that delay generic entry in exchange for royalties or market-share economics
• Co-promotion or distribution rights that lock in channel access during patent gaps
• Settlement terms tied to specific launch dates and specific generic strength/dosage forms

Investment effect

A settlement that restricts entry for a defined period can shift the valuation from “patent cliff” to “extended cashflow runway.” Absent enforceable claims or settlements, TRIOSTAT behaves like a high-substitution category asset.

---

Key takeaways

• TRIOSTAT’s investment fundamentals depend primarily on whether it is protected by enforceable, specific Orange Book patents covering a distinct branded formulation or method, not only by active-ingredient coverage.
• OAB antimuscarinics have high generic substitution risk driven by AB-rating and payer preference; upside requires defensible formulation or process differentiation.
• The generic entry schedule and litigation posture must be anchored to TRIOSTAT’s Orange Book listing, with patent-by-patent expiration and claim scope used to model launch scenarios.
• Without a confirmed, listing-specific IP and FDA mapping, any precise exclusivity date or litigation forecast cannot be grounded in hard inputs.

---

FAQs

1. How do AB-rating and formulary tiering affect TRIOSTAT pricing after generic oxybutynin entry?
2. What patent claim types (composition vs method-of-use vs process) typically create the most generic-entry friction for OAB antimuscarinics?
3. How is Paragraph IV timing for oxybutynin-related products usually influenced by Orange Book listing density?
4. Does a switch from antimuscarinics to beta-3 agonists (mirabegron/vibegron) change TRIOSTAT’s addressable market more than generic entry does?
5. What settlement terms most often govern whether generic launches cluster after a single patent expires?

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/